1-3 of 3
Fredrik H. Schjesvold, MDPhD
Close
Sort by
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018
Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos, MD, Francesca Gay, MDPhD, Fredrik H. Schjesvold, MDPhD, Meral Beksac, MD, Roman Hajek, Katja Weisel, MD, Hartmut Goldschmidt, MD, Vladimir Maisnar, MD, Philippe Moreau, Chang-Ki Min, MD PhD, Agnieszka Pluta, MD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Martin Kaiser, MD, Sonja Zweegman, MDPhD, Maria-Victoria Mateos, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shinsuke Iida, MDPhD, Gareth Morgan, MD, Zhaoyang Teng, PhD, Kaveri Suryanarayan, MD, Tomas Skacel, MD PhD, Ajeeta B Dash, PhD, Richard Labotka, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 301.
https://doi.org/10.1182/blood-2018-99-112079
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

Sonja Zweegman, MD PhD, Bronno van der Holt, Fredrik H. Schjesvold, MDPhD, Mark-David Levin, PhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria Berhardina Leijs, MD, Saskia Klein, MD, Damian L. Szatkowski, MDPhDMSc, A Broyl, MDPhD, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MD, Asta Svirskaite, Sonia Cunha, Markus Hansson, MD PhD, Pieter Sonneveld, MDPhD, Einar Haukaas, Niels Abildgaard, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 433.
https://doi.org/10.1182/blood.V130.Suppl_1.433.433
Published: 2017